The Conversation (0)
CorMedix secured a research grant from the National Institutes of Health to expand the Company’s antimicrobial hydrogel medical device program.
CorMedix (NYSE:CRMD) secured a research grant from the National Institutes of Health to expand the Company’s antimicrobial hydrogel medical device program.
As quoted in the press release:
In addition to CorMedix’s ongoing development of taurolidine-incorporated hydrogels to reduce infections in common burns, this funding will finance the development of an advanced hydrogel formulation that is designed to reduce the risk of potentially life-threatening infection and promote healing of more severe burn injuries, for which there is significant need.
Khoso Baluch, CorMedix Chief Executive Officer stated, “This grant funding enables CorMedix to broaden our anti-infective hydrogel development program and validates our scientific approach to the use of taurolidine in a variety of certain medical device applications. We are pleased to be awarded this grant, which was based on a Request for Proposal from the NIH to address the need for antiseptic products that can penetrate to the site of infection in deeper, more severe burns. With access to this capital, we can pursue development of this advanced hydrogel formulation in parallel with our first-generation taurolidine-based hydrogels intended to treat common topical burns, rather than in sequence. It may also provide a second near-term hydrogel product opportunity for CorMedix without drawing from our current cash.”
Click here to read the full press release.
Source: www.accesswire.com
